What is Lifesci Capital's Estimate for PVLA Q2 Earnings?

Key Points

• Analysts at Lifesci Capital have issued forecasts for Palvella Therapeutics, predicting Q2 2025 earnings per share (EPS) of ($0.77), with a full-year estimate of ($3.69) EPS for 2025.
• Palvella Therapeutics has an average analyst rating of "Buy" with a consensus target price of $52.40.
• Recently, large institutional investors have increased their stake in Palvella Therapeutics, now holding 40.11% of the company's stock.

Palvella Therapeutics, Inc. (NASDAQ:PVLA - Free Report) - Research analysts at Lifesci Capital issued their Q2 2025 earnings per share (EPS) estimates for Palvella Therapeutics in a report released on Monday, August 4th. Lifesci Capital analyst S. Slutsky forecasts that the company will post earnings per share of ($0.77) for the quarter. Lifesci Capital currently has a "Outperform" rating and a $90.00 price target on the stock. The consensus estimate for Palvella Therapeutics' current full-year earnings is ($3.69) per share. Lifesci Capital also issued estimates for Palvella Therapeutics' Q3 2025 earnings at ($0.81) EPS, Q4 2025 earnings at ($0.81) EPS, FY2025 earnings at ($3.13) EPS and FY2026 earnings at ($3.64) EPS.

A number of other brokerages have also recently issued reports on PVLA. Canaccord Genuity Group reduced their price objective on Palvella Therapeutics from $53.00 to $52.00 and set a "buy" rating on the stock in a research note on Friday, May 16th. HC Wainwright reaffirmed a "buy" rating and set a $38.00 price objective on shares of Palvella Therapeutics in a research note on Wednesday, April 30th. Truist Financial assumed coverage on Palvella Therapeutics in a research note on Monday, July 21st. They set a "buy" rating and a $56.00 price objective on the stock. Finally, Raymond James Financial assumed coverage on Palvella Therapeutics in a research note on Tuesday. They issued an "outperform" rating and a $54.00 target price on the stock. Ten research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, Palvella Therapeutics currently has an average rating of "Buy" and a consensus target price of $52.40.

Palvella Therapeutics Trading Up 4.7%

Shares of NASDAQ:PVLA traded up $1.85 on Wednesday, reaching $40.90. 106,508 shares of the company traded hands, compared to its average volume of 187,830. The business's 50-day simple moving average is $28.49 and its 200 day simple moving average is $24.23. Palvella Therapeutics has a 52 week low of $11.17 and a 52 week high of $41.00. The stock has a market capitalization of $452.35 million, a P/E ratio of -3.38 and a beta of -0.01.

Palvella Therapeutics (NASDAQ:PVLA - Get Free Report) last announced its quarterly earnings data on Thursday, May 15th. The company reported ($0.74) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($3.40) by $2.66.

Institutional Trading of Palvella Therapeutics

Several large investors have recently bought and sold shares of the company. Suvretta Capital Management LLC bought a new stake in shares of Palvella Therapeutics in the 4th quarter worth approximately $8,574,000. BVF Inc. IL bought a new stake in shares of Palvella Therapeutics in the 4th quarter worth approximately $8,359,000. Frazier Life Sciences Management L.P. boosted its position in shares of Palvella Therapeutics by 5.5% in the 1st quarter. Frazier Life Sciences Management L.P. now owns 690,012 shares of the company's stock worth $19,313,000 after purchasing an additional 36,120 shares in the last quarter. Samsara BioCapital LLC bought a new stake in shares of Palvella Therapeutics in the 4th quarter worth approximately $8,154,000. Finally, Adams Street Partners LLC bought a new stake in shares of Palvella Therapeutics in the 4th quarter worth approximately $4,916,000. 40.11% of the stock is owned by institutional investors.

Palvella Therapeutics Company Profile

Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc, formerly known as Pieris Pharmaceuticals Inc, is based in WAYNE, Pa.